Year: 2021

Jaguar Health Announces Closing of $6.0 Million Issuance and Sale of Designation-backed Note Related to Possible Tropical Disease Priority Review Voucher

This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and...

Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil

GENEVA, SWITZERLAND and GUNDELFINGEN, GERMANY / ACCESSWIRE / January 20, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief"), a biopharmaceutical...

Antisense Oligonucleotide Candidate Derived from Secarna Pharmaceuticals’ LNAplusTM Platform has Entered Pre-Clinical Safety Trials for the Treatment of Elevated Blood Lipids

Secarna's partner Lipigon has selected an LNAplusTM ASO candidate targeting ANGPTL4, called Lipisense, which has shown unique efficacy in reducing...

error: Content is protected !!